- Home
- RYET vs MDWD Comparison
RYET vs MDWD Comparison
Compare RYET & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYET
- MDWD
- Stock Information
- Founded
- RYET 2012
- MDWD 2000
- Country
- RYET China
- MDWD Israel
- Employees
- RYET N/A
- MDWD N/A
- Industry
- RYET
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- RYET
- MDWD Health Care
- Exchange
- RYET NYSE
- MDWD Nasdaq
- Market Cap
- RYET 206.2M
- MDWD 208.2M
- IPO Year
- RYET 2025
- MDWD 2014
- Fundamental
- Price
- RYET $19.66
- MDWD $20.72
- Analyst Decision
- RYET
- MDWD Strong Buy
- Analyst Count
- RYET 0
- MDWD 2
- Target Price
- RYET N/A
- MDWD $35.00
- AVG Volume (30 Days)
- RYET 458.1K
- MDWD 50.6K
- Earning Date
- RYET 01-01-0001
- MDWD 08-13-2025
- Dividend Yield
- RYET N/A
- MDWD N/A
- EPS Growth
- RYET N/A
- MDWD N/A
- EPS
- RYET N/A
- MDWD N/A
- Revenue
- RYET $6,989,985.00
- MDWD $19,213,000.00
- Revenue This Year
- RYET N/A
- MDWD $20.80
- Revenue Next Year
- RYET N/A
- MDWD $26.92
- P/E Ratio
- RYET N/A
- MDWD N/A
- Revenue Growth
- RYET N/A
- MDWD N/A
- 52 Week Low
- RYET $2.68
- MDWD $14.14
- 52 Week High
- RYET $21.00
- MDWD $22.51
- Technical
- Relative Strength Index (RSI)
- RYET N/A
- MDWD 64.88
- Support Level
- RYET N/A
- MDWD $19.07
- Resistance Level
- RYET N/A
- MDWD $19.55
- Average True Range (ATR)
- RYET 0.00
- MDWD 0.65
- MACD
- RYET 0.00
- MDWD 0.12
- Stochastic Oscillator
- RYET 0.00
- MDWD 94.01
About RYET RUANYUN EDAI TECHNOLOGY INC
Ruanyun Edai Technology Inc is primarily engaged in providing online academic exercise question banks with A.I. capabilities, online classes and homework, and on-demand lectures and evaluations that cover all K-12 subject fields and grade levels.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.